Simple Signaling Molecules for Inductive Bone Regenerative Engineering by Ulery, Bret D. et al.
University of Connecticut
OpenCommons@UConn
UCHC Articles - Research University of Connecticut Health Center Research
7-14-2014
Simple Signaling Molecules for Inductive Bone
Regenerative Engineering
Bret D. Ulery
University of Connecticut School of Medicine and Dentistry
Stephen J. Nelson
University of Connecticut School of Medicine and Dentistry
Meng Deng
University of Connecticut School of Medicine and Dentistry
Kevin W. H. Lo
University of Connecticut School of Medicine and Dentistry
Yusuf M. Khan
University of Connecticut - Storrs
See next page for additional authors
Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons
Recommended Citation
Ulery, Bret D.; Nelson, Stephen J.; Deng, Meng; Lo, Kevin W. H.; Khan, Yusuf M.; and Laurencin, Cato T., "Simple Signaling
Molecules for Inductive Bone Regenerative Engineering" (2014). UCHC Articles - Research. 246.
https://opencommons.uconn.edu/uchcres_articles/246
Authors
Bret D. Ulery, Stephen J. Nelson, Meng Deng, Kevin W. H. Lo, Yusuf M. Khan, and Cato T. Laurencin
This article is available at OpenCommons@UConn: https://opencommons.uconn.edu/uchcres_articles/246
Simple Signaling Molecules for Inductive Bone
Regenerative Engineering
Emily K. Cushnie3.¤a, Bret D. Ulery1,2,4.¤b, Stephen J. Nelson5, Meng Deng1,2,4,
Swaminathan Sethuraman6, Stephen B. Doty7, Kevin W. H. Lo1,8, Yusuf M. Khan1,2,4,9,
Cato T. Laurencin1,2,4,10*
1 Institute for Regenerative Engineering, University of Connecticut Health Center, Farmington, Connecticut, United States of America, 2 Raymond and Beverly Sackler
Center for Biological, Physical and Engineering Sciences, University of Connecticut Health Center, Farmington, Connecticut, United States of America, 3Department of
Chemical Engineering, University of Virginia, Charlottesville, Virginia, United States of America, 4Department of Orthopaedic Surgery, University of Connecticut Health
Center, Farmington, Connecticut, United States of America, 5 School of Medicine, University of Connecticut Health Center, Farmington, Connecticut, United States of
America, 6Center for Nanotechnology & Advanced Biomaterials, School of Chemical & Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India, 7Hospital for
Special Surgery, New York, New York, United States of America, 8Department of Medicine, Division of Endocrinology, University of Connecticut Health Center,
Farmington, Connecticut, United States of America, 9Department of Materials Science and Engineering, University of Connecticut, Storrs, Connecticut, United States of
America, 10Department of Chemical and Biomolecular Engineering, University of Connecticut, Storrs, Connecticut, United States of America
Abstract
With greater than 500,000 orthopaedic procedures performed in the United States each year requiring a bone graft, the
development of novel graft materials is necessary. We report that some porous polymer/ceramic composite scaffolds
possess intrinsic osteoinductivity as shown through their capacity to induce in vivo host osteoid mineralization and in vitro
stem cell osteogenesis making them attractive synthetic bone graft substitutes. It was discovered that certain low
crystallinity ceramics partially dissociate into simple signaling molecules (i.e., calcium and phosphate ions) that induce stem
cells to endogenously produce their own osteoinductive proteins. Review of the literature has uncovered a variety of simple
signaling molecules (i.e., gases, ions, and redox reagents) capable of inducing other desirable stem cell differentiation
through endogenous growth factor production. Inductive simple signaling molecules, which we have termed inducerons,
represent a paradigm shift in the field of regenerative engineering where they can be utilized in place of recombinant
protein growth factors.
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Introduction
It is estimated that 50% of Americans will suffer from a
traumatic bone fracture that requires orthopaedic services before
the age of 65 [1], many of which will require the use of bone grafts
such as autografts (the patient’s own tissue) or allografts (another
person’s tissue). Unfortunately, autografts are of limited supply and
can cause significant pain at the graft donor site [2,3], and
allografts have the potential to transmit disease and induce an
undesirable immune response [4,5]. To overcome these issues,
bone graft substitutes have been heavily researched and are now
utilized in approximately 18–20% of all grafting procedures [6].
Some of the most clinically successful bone graft substitutes utilize
scaffold-based systems for the spatio-temporally controlled delivery
of recombinant human bone morphogenetic proteins (rhBMPs)
[7,8]. While promising, rhBMPs have been plagued by concerns
associated with their high cost (in some cases $5,000 a dose) [9],
supraphysiological dosage requirements (,1 million times phys-
iological concentrations) [10], unwanted immunological reactions
[11], and undesirable ectopic tissue development [12]. By
engineering novel materials-based systems capable of adjuvanting
the effects of rhBMPs or replacing them all together, clinical
outcomes can be significantly improved while also greatly
decreasing costs.
One materials-based approach is to create scaffolds that
replicate the organic (i.e. protein) and inorganic (i.e. ceramic)
components of native bone. By choosing degradable materials,
scaffolds can be fabricated that provide initial support for
infiltrating host cells but can be resorbed and replaced as the
host regenerates its own tissue. Polymers are suitable organic-
phase substitutes since they are biocompatible and possess similar
tensile strength to natural bone. Poly(lactide-co-glycolide) (PLGA)
is a commonly utilized hydrolytically degradable polymer that is
osteocompatible [13] and has been cleared by the Food and Drug
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e101627
Administration for many indications. Hydroxyapatite (HA) is a
calcium phosphate (CaP) which is the main inorganic component
of bone [14]. It possesses high compressive strength [15] and is
osteoconductive (allows for bone cell attachment, migration, and
growth) [16] making it an ideal inorganic material for bone tissue
engineering. Through the combination of PLGA and HA, we
believe that a composite scaffold can be created that capitalizes on
the benefits of both materials.
Previously, PLGA and PLGA/HA scaffolds have been fabri-
cated by forming microspheres using emulsion solvent evaporation
techniques and melt-sintering them into porous three-dimensional
constructs [17–19]. PLGA and PLGA/HA scaffolds have been
shown to possess mechanical properties similar to trabecular bone
making them ideal graft substitutes for bone regenerative
engineering applications [13,17,19]. Here, in vivo and in vitro
analysis of PLGA/HA scaffolds revealed that these biomaterials
possess intrinsic osteoinductivity. The theory we propose for this
behavior represents a fundamental change in how regenerative
engineering methodologies will be approached henceforth.
Materials and Methods
Materials
85:15 poly(lactide-co-glycolide) (PLGA) with a MW of
,94,000 Da was purchased from Lakeshore Biomaterials (Bir-
mingham, AL). Methylene chloride, calcium nitrate tetrahydrate,
ammonium hydrogen phosphate, and polyvinyl alcohol (PVA)
(MW ,70,000 Da) were acquired from Fisher Scientific (Pitts-
burgh, PA). Ammonium hydroxide, collagenase type I, ascorbic
acid, b-glycerophosphate, vitamin D3, and cetylpyridinium
chloride (CPC) were obtained from Sigma-Aldrich (St. Louis,
MO). Dulbecco’s Phosphate-Buffered Saline (PBS) and 0.05%
trypsin-EDTA solution were purchased from Gibco (Grand Island,
NY). Dulbecco’s Modified Eagle Medium (DMEM), penicillin-
streptomycin solution (Pen-Strep), and fetal bovine serum (FBS)
were procured from Invitrogen Corporation (Carlsbad, CA).
Triton X-100 was bought from Bio-Rad Laboratories, Inc.
(Hercules, CA). Recombinant human bone morphogenetic pro-
tein-2 (rhBMP-2) was purchased from GenScript Corporation
(Piscataway, NJ).
Microsphere fabrication
The method for synthesizing PLGA microspheres and PLGA/
hydroxyapatite (PLGA/HA) composite microspheres by a double
emulsion solvent evaporization technique has been previously
described in detail [20–23]. PLGA microspheres were fabricated
by adding an organic solution of PLGA in methylene chloride
(160 mg/mL) via a thin stream into a 1% PVA solution mixed by
an overhead stirrer (250 RPM) for 24 hours at room temperature.
PLGA/HA microspheres were fabricated by first separately
preparing 1.5 mL of 10 M calcium nitrate tetrahydrate (Ca(NO3)2
N 4 H2O) solution and 2.25 mL of 4 M ammonium hydrogen
phosphate ((NH4)2HPO4) solution in distilled, deionized water
(ddH2O). These salt solutions at a calcium/phosphate molar ratio
of 1.67 were emulsified together in an organic solution of PLGA in
methylene chloride (125 mg/mL) by vortexing. Two different
volumes of PLGA solution (24 mL and 12 mL) were used resulting
in mass ratios of polymer to ceramic reactants of 40:60 and 20:80
which resulted in final polymer/ceramic microsphere composi-
tions of 83/17 PLGA/HA and 73/27 PLGA/HA, respectively.
The mixture was added by a thin stream to a 1% PVA solution
mixed by an overhead stirrer (250 RPM) for 24 hours at 4uC. A
Titrino pH STAT (Metrohm, Herisau, Switzerland) was used to
add ammonium hydroxide solution to the emulsion solution in
order to maintain a pH of 10. Solidified microspheres were
isolated from surfactant solution via decantation and vacuum
filtration, rinsed with ddH2O, and lyophilized overnight. Dried
microspheres were sieved to a diameter range of 355–600 mm
using stainless steel sieves (Newark Wire Cloth Company, Clifton,
NJ) since microspheres in this size range have been shown to yield
scaffolds with a desirable pore size range of 100–350 mm [17].
Microspheres were then stored under desiccant until further use.
Three-dimensional porous scaffold fabrication
For scaffold fabrication, 355–600 mm microspheres were loaded
into a 5 mm610 mm stainless steel mold and compressed with a
piston to achieve desired packing. The mold was heated at 90uC
for 90 minutes to melt sinter microspheres together at their
intersection points. Scaffolds were allowed to cool to room
temperature slowly and then removed from the mold. Scaffolds
fabricated for in vitro experiments were cut in half (5 mm65 mm)
using a microtome blade. Scaffold morphology was assessed by
scanning electron microscopy (SEM) using a JEOL JSM-6335F
(JEOL Ltd., Tokyo, Japan) as described previously [17]. Scaffolds
were stored under desiccant until further use. Immediately before
being utilized for in vivo and in vitro experiments, scaffolds were
sterilized to prevent contamination by being submerged in 70%
ethanol, washed with ddH2O, and exposed to UV light.
Ulnar non-union defect and radiographical analysis
Surgical procedures as well as pre- and post-surgical care were
performed as specified by Animal Care and Use Committee
approved protocols similarly to previously reported methods
[18,24]. Male New Zealand White rabbits (4–5 kg) were
anesthetized with a cocktail of ketamine, xylazine, and acepro-
mazine. The right forelimb of the animal was shaved and
aseptically prepared with betadine and 70% ethanol. An incision
(,15 mm) was made above the ulna and soft tissue was resected
away from the bone. A 10 mm ulnar segment was removed using
an oscillating saw irrigated with saline. PLGA, 83/17 PLGA/HA,
or 73/27 PLGA/HA scaffolds (5 mm610 mm, N=10) were
implanted into the defect site. The wound was closed in layers with
degradable sutures used for the deep tissue layers and wound clips
used for the skin. Pain was managed by pre-operative and post-
operative injections of Buprenex and a Duragesic patch (25 ug) for
the first 72 hours after surgery. Animals were given prophylactic
doses of Baytril (Enrofloxacin) the day before surgery, the day of
surgery, and the three days following surgery. Animals were fed
ad-libitum and permitted to roam freely within their cages after
surgery. The radius acts as a natural splint for the ulna, so no
external fixation was used to secure the ulna. Radiographs were
taken of the scaffold implanted ulnae immediately after surgery
and every four weeks for the duration of the study with an OEC
8800 Digital Imaging System (GE Healthcare, Little Chalfont,
UK) to track healing patterns.
Histological analysis
Animals were euthanized at 8 weeks post-operation and limbs
were prepared for histology. Limbs were immersed in 10%
formalin for 5 days, soft tissue was resected away from the bone,
and the ulna was cut 5 mm proximal and distal to the implanted
scaffolds. Samples were then placed in fresh 10% formalin for an
additional 48 hours and transferred to 50% ethanol for storage.
For sectioning, samples were cold embedded in polymethylmetha-
crylate (PMMA) for 3–8 days at 220uC to minimize PMMA
exothermic curing effects. Embedded sections were cut into 10 mm
thick sections and mounted on glass slides. Tissue sections were
stained with Von Kossa stain to identify areas of mineralization
Simple Signaling Molecules
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(black) with a cellular counter stain (neutral red). Histological
samples were visualized using an Axiovert 135 light microscope
(Carl Zeiss AG, Oberkochen, Germany) and images were taken
using a MicroFire digital microscope camera (Optronics, Goleta,
CA).
Adipose derived mesenchymal stem cell (MSC) isolation
and culture
Cellular isolation procedures were performed as specified by
protocols approved by the University of Virginia Internal Review
Board. Human infrapatellar fat pads were obtained from patients
undergoing routine total knee arthroplasties at the University of
Virginia Hospital. Samples were moved to a sterile cell culture
hood where they were rinsed with filter sterilized PBS and minced.
An equal volume of 0.1% collagenase type I solution was added to
minced sample suspensions and allowed to incubate on a tilting
table for 45 minutes at 37uC. Following digestion, the collagenase
was neutralized with FBS. The infranatant was transferred to a
new tube and centrifuged at 1,200 g for 10 minutes. The fat-
enriched supernatant was discarded leaving behind a cell pellet.
The pellet was resuspended in DMEM containing 10% FBS and
passed through a 100 mm nylon mesh cell filter (Fisher Scientific,
Pittsburgh, PA). The filtrate was collected and centrifuged at
12,000 g for 10 minutes. The supernatant was discarded leaving
behind a cell pellet rich in adipose derived MSCs. The MSCs were
resuspended in growth media (DMEM supplemented with 10%
FBS, 100 units/mL Penicillin, and 100 mg/mL Streptomycin) and
then plated on T-75 cell culture flasks (Becton Dickinson, Franklin
Lakes, NJ) with growth media changed every 72 hours. Cells were
grown to ,70% confluency, lifted from flasks by exposure to
0.05% trypsin-EDTA solution, counted using a hemocytometer,
and then passed to new flasks. After 5 passages, MSCs were
cryogenically frozen in liquid nitrogen in aliquots of 1 million cells
per vial for later use. When a cell study was to be started, frozen
MSCs were thawed in a 37uC water bath, diluted in growth
media, transferred to T-75 flasks, and cultured as previously
described. Cells were passed once and then suspended at a stock
concentration of 1.67 million cells per mL for in vitro cell studies.
In vitro adipose derived mesenchymal stem cell (MSC)
seeded scaffold studies
PLGA, 83/17 PLGA/HA, and 73/27 PLGA/HA scaffolds
(5 mm65 mm) were placed in 24 well plates (Becton Dickinson,
Franklin Lakes, NJ), and carefully loaded with 30 uL of stock
MSC solution (50,000 cells). MSCs were allowed to adhere to the
scaffolds for 10 minutes and then cellularized scaffolds were
transferred to new 24 well plates with 1 mL of osteogenic media
(DMEM supplemented with 10% FBS, 100 units/mL Penicillin,
100 mg/mL Streptomycin, 50 mM ascorbic acid, 10 mM b-
glycerophosphate, and 10 nM vitamin D3). Tissue cultured
polystyrene (TCP) was utilized as a control and also loaded with
50,000 MSC per well in 1 mL osteogenic media. MSCs were
cultured for up to 21 days at 37uC and 5% CO2 and media was
changed every 72 hours. Cellular morphology at day 21 was
analyzed using SEM. Proliferation, protein secretion, and miner-
alization were assessed at 3, 7, 14, and 21 days. A sample size of 4
was used for all experiments.
Cellular morphology and proliferation assay
Prior to imaging, cellularized scaffolds were exposed to series
dilutions of gluteraldehyde (1% for 1 hour and 3% for 24 hours)
and ethanol (30%, 50%, 70%, and 100% for 1 hour each), and
then air-dried for 24 hours. Scaffolds were analyzed by SEM in
triplicate at different magnifications. Additionally, at each time
point, media was removed from the wells and the contents were
rinsed with PBS. Scaffolds were transferred to new well plates to
ensure that cells not adhered to the scaffolds were not counted.
Following the rinse, cells were exposed to 1 mL of 1% Triton X-
100 and treated with 3 freeze-thaw cycles to induce complete cell
lysis. Lysates were analyzed by the Quant-iT PicoGreen dsDNA
Assay (Molecular Probes, Invitrogen, Eugene, OR) using a
Synergy HT microplate reader (Biotek, Winooski, VT) at an
excitation wavelength of 480 nm and an emission wavelength of
520 nm. Fluorescence was converted to cell number using an
adipose derived MSC cell count standard (0–800,000 cells/mL).
Osteocalcin (OCN) and Bone Morphogenetic Protein-2
(BMP-2) secretion assays
Twenty-four hours prior to each time point, media was
removed from the wells, samples were washed with PBS, and
fresh media without FBS was added. Scaffolds were transferred to
new well plates to ensure that only protein production from
scaffold adhered cells would be quantified. At each time point, the
FBS-free media was removed from the samples and stored at -
20uC until analyzed for protein production. An intact human
OCN enzyme-linked immunosorbent assay (ELISA) kit (Biomed-
ical Technologies Incorporated, Stoughton, MA) was used to
quantify cell secreted OCN. The assay product solution was
visualized using a Biotek Synergy HT microplate reader at a
wavelength of 450 nm. The absorbance was converted to OCN
concentration with the use of a kit provided human OCN standard
(0–50 ng/mL) and then was normalized by cell count. An intact
human Quantikine BMP-2 ELISA kit (R&D Systems, Minneap-
olis, MN) was used to quantify cell secreted BMP-2. The assay
product solution was visualized using a Biotek Synergy HT
microplate reader at a wavelength of 450 nm. The absorbance
was converted to BMP-2 concentration with the use of a kit
provided human BMP-2 standard (0–4,000 pg/mL) and then was
normalized by cell count.
Mineralization Assay
At each time point, media was removed from the wells, the
contents were rinsed with ddH2O, and fixed in 70% ethanol for
24 hours. Scaffolds were transferred to new wells plates to ensure
that only scaffolds associated mineralization would be quantified.
Acellular scaffolds were exposed to the same culture conditions as
the cellularized scaffolds in order to determine the extent of
background mineralization due to scaffold-based and/or precip-
itated calcium phosphate. Following fixation, ethanol was removed
and the samples were incubated in 1 mL of 40 mM alizarin red
solution (pH 4.23) which binds to calcium phosphate. After 10
minutes, the samples were thoroughly rinsed with ddH2O until all
non-adsorbed stain was removed. When completely air dried,
stained scaffolds were imaged using a Stereo Discovery V12
stereoscope (Carl Zeiss AG, Oberkochen, Germany). Sample
associated alizarin red was desorbed using 1 mL of 10% CPC
solution (pH 7.0) and concentration was analyzed using a Biotek
Synergy HT microplate reader at a wavelength of 550 nm.
Absorbance was converted to alizarin red concentration using a
standard curve in the linear range (0–0.2740 mg/mL). Sample
concentrations that were above the linear absorption range were
serially diluted with CPC until they could be quantified. Cell-
based mineral deposition was calculated as the difference in
mineralization between acellular and cellularized scaffolds and
normalized by cell count.
Simple Signaling Molecules
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Scaffold ion release study
PLGA, 83/17 PLGA/HA, and 73/27 PLGA/HA scaffolds
(5 mm65 mm) were loaded in polystyrene microcentrifuge tubes
(Thermo Fisher Scientific, Waltham, MA) with 1 mL calcium-free
PBS and incubated on a tilting table at 37uC. Aliquots of
supernatant (0.5 mL) were collected daily and replaced with fresh
PBS for 21 days. Sample calcium ion content was assessed by a
Calcium (CPC) Liquicolor Assay Kit (Stanbio Laboratories, Palo
Alto, CA) and cumulative calcium ion release was plotted as a
function of time.
Scaffold rhBMP-2 adsorption
Lyophilized rhBMP-2 was reconstituted in 20 mM acetic acid
and then used to prepare 30, 125, and 500 mg/mL rhBMP-2
loading solutions in aqueous glutamate-based buffer (5 mM
glutamate, 0.5% sucrose, 2.5% glycine, 0.01% Tween 80,
pH 4.5). PLGA and 83/17 PLGA/HA scaffolds were sterilized
by being submerged in 70% ethanol and then washed with sterile
ddH2O. Protein solutions (30 mL) were slowly dripped on to
corresponding scaffolds yielding final rhBMP-2 loadings of 0.9 mg,
3.75 mg, and 15 mg. Protein loaded scaffolds were allowed to air
dry in a sterile cell culture hood, lyophilized for 24 hours, and
sterilized by exposure to UV light.
In vitro MSC seeded rhBMP-2 loaded scaffolds studies
PLGA scaffolds, rhBMP-2 (0.9 mg, 3.75 mg, or 15 mg) loaded
PLGA scaffolds, 83/17 PLGA/HA scaffolds, rhBMP-2 (0.9 mg,
3.75 mg, or 15 mg) loaded 83/17 PLGA/HA scaffolds, and TCP
were seeded with MSCs as described for the previous study and
cultured in osteogenic media for up to 21 days. Proliferation, OCN
secretion, and mineralization were assessed at 3, 7, 14, and 21 days
as described above. Cell secreted BMP-2 was determined as the
difference between the BMP-2 measured for acellular and
cellularized scaffolds using a BMP-2 ELISA kit.
Cumulative BMP-2 release study
PLGA and 83/17 PLGA/HA scaffolds were either seeded with
MSCs or loaded with rhBMP-2 as described above and cultured in
osteogenic media for 21 days. Each day, media was removed from
the samples, stored at 220uC, and replaced with fresh media.
After 21 days, all samples were analyzed for their BMP-2 content
using a BMP-2 ELISA kit. The kit provided human BMP-2
standard (0–4,000 pg/mL) was used to quantify cell secreted
BMP-2, whereas a rhBMP-2 standard (0–4,000 ng/mL) was used
to quantify protein released from the rhBMP-2 loaded scaffolds.
Cumulative BMP-2 was plotted as a function of time.
Statistical analysis
All results in the figures are reported as mean 6 standard
deviation. JMP software (SAS Institute, Cary, NC) was used to
make comparisons between groups using an ANOVA followed by
Tukey’s HSD test to determine pairwise statistically significant
differences (p,0.05).
Results
Composite scaffold-mediated in vivo neo-bone formation
PLGA/HA composite scaffolds were created by first precipitat-
ing HA into PLGA microspheres in situ using a double emulsion
solvent evaporation technique and then melt-sintering the
microspheres into three-dimensional cylindrical scaffolds as
described previously [19]. Scaffolds composed of PLGA and two
different compositions of PLGA/HA (83/17 and 73/27 weight
ratios) were evaluated in this research. Scanning electron
microscopy revealed porous three-dimensional scaffolds comprised
of microspheres with melted intersection points regardless of
scaffold composition (Fig. 1A). Microtopographically, PLGA
scaffolds had a smooth surface whereas both PLGA/HA scaffolds
possessed a rough surface attributable to the in situ precipitated HA
present on the microsphere surface. All three compositions of
scaffolds were implanted in rabbit ulnar segmental non-union
defects and radiographs were taken throughout the healing process
(Fig. 1B). Immediately after implantation (0 weeks), the defect was
clearly visible in the mid-region of the ulna. At 4 weeks post-
implantation, the defects showed signs of early healing at the
scaffold-bone interface. By 8 weeks post-implantation, radiograph-
ic evidence of mineralized callus formation was seen as well as
complete bridging along the medial half of the defect for both the
PLGA and 83/17 PLGA/HA scaffolds. For the 73/27 PLGA/HA
scaffolds, abundant healing along the medial half of the defect with
nearly complete bridging was seen. These results provide evidence
that bone healing proceeded across the defect regardless of scaffold
type. Animals were euthanized at 8 weeks and tissue samples were
sectioned and stained with von Kossa stain. Histological analysis of
resected samples showed tissue ingrowth throughout the micro-
sphere structure of all scaffolds regardless of composition (Fig. 1C).
However, there were significant differences between the mineral-
ization seen in PLGA scaffolds compared to both PLGA/HA
scaffolds. PLGA scaffolds showed no dark staining at the host
interface indicating a lack of mineralized tissue. In contrast, both
PLGA/HA scaffolds showed significant positive mineral staining
at their host interfaces as well as within the edges of the scaffold
interior. Specifically, the 73/27 PLGA/HA scaffolds showed
incorporation of the microsphere matrix by the host osteoid tissue
(Fig. 1D). Mononuclear cells were found in a band along von
Kossa stained calcium phosphate (CaP) analogous to osteoblasts
lining up along mineralizing fronts of remodeled bone tissue. This
behavior was not seen with the PLGA scaffolds and is similar to
results seen with other polymer/CaP constructs [25,26] suggesting
that the HA component in PLGA/HA scaffolds can induce new
mineralized bone growth without the inclusion of exogenous
growth factors or cells.
Composite scaffold-mediated in vitro stem cell
differentiation
The osteoinductivity of PLGA/HA scaffolds was studied further
through in vitro experimentation using human adipose-derived
mesenchymal stem cells (MSCs). Human adipose-derived MSCs
were chosen since they are easy to extract from the host and
culture into highly pure populations [27]. MSCs were seeded and
cultured for up to 21 days on tissue culture polystyrene (TCP),
PLGA scaffolds, 83/17 PLGA/HA scaffolds, or 73/27 PLGA/HA
scaffolds. Scanning electron microscopy confirmed that MSCs
were able to span scaffold pore spaces by utilizing filopodia to
attach to microsphere surfaces and were found to be evenly
distributed throughout the scaffolds regardless of scaffold compo-
sition (data not shown). At 3, 7, 14, and 21 days, cells were assessed
for their proliferation and osteogenic differentiation. MSCs
cultured on TCP or PLGA scaffolds showed statistically significant
increases in cell number over time, whereas cells cultured on either
of the PLGA/HA scaffold compositions showed limited increases
in cell number over time (Fig. 2A). By 21 days, significantly higher
cell counts were found for MSCs seeded on TCP or PLGA
scaffolds than those seeded on PLGA/HA scaffolds. Lower cellular
proliferation on PLGA/HA scaffolds suggests potential cellular
differentiation. In order to determine if MSCs were differentiating
down the osteoblastic lineage, cellular secretion of the pro-
Simple Signaling Molecules
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Figure 1. In vivo osteoinductivity of PLGA/HA composite scaffolds. (A) Representative scanning electron micrographs of sintered
microsphere scaffolds (Scale Bar = 100 mm). (B) Representative radiographs of 10 mm rabbit ulnar non-union segmental defects loaded with different
scaffold compositions. (C) Optical micrographs of histological sections stained with von Kossa stain at 8 weeks (MS= Microsphere Scaffold, O =
Osteoid, BM= Bone Marrow; Magnification = 40x). (D) Von Kossa staining of the histological sections for the 73/27 PLGA/HA composite scaffolds
show the incorporation of microspheres into newly forming mineralized osteoid bone. The blue ellipsoid signifies the next field of view;
Magnification = 40x (left), 100x (center), and 320x (right).
doi:10.1371/journal.pone.0101627.g001
Simple Signaling Molecules
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osteoblastic protein osteocalcin (OCN) and cell-based mineral
deposition were analyzed. OCN secretion was assayed by an
enzyme-linked immunosorbent assay (ELISA) and significant
differences were seen between the experimental groups (Fig. 2B).
MSCs grown on TCP and PLGA scaffolds had non-detectable and
barely detectable levels of OCN secretion, respectively. In
contrast, MSCs grown on either of the PLGA/HA scaffold
compositions showed statistically significant increases in OCN
secretion over time, providing evidence that the MSCs were
differentiating into osteoblasts. Mineral deposition was assayed by
alizarin red stain, which tightly binds calcium and calcium
composites. Sterioscopic images showed alizarin red staining of the
CaP on the surface of acellular PLGA/HA scaffolds as expected,
but a deeper red color was present on the MSC-seeded PLGA/
HA scaffolds, which indicated additional, cell-based, mineral
deposition (data not shown). Alizarin red stain was desorbed from
the scaffolds and spectrophotometrically analyzed with acellular
staining subtracted in order to determine cell-based mineraliza-
tion. MSCs incubated on either PLGA/HA scaffold composition
deposited statistically significant greater quantities of mineral
compared to nearly non-detectable levels of mineral deposition by
cells incubated on TCP or PLGA scaffolds (Fig. 2C). Together,
these in vivo and in vitro data provide significant evidence that HA
containing scaffolds may be intrinsically osteoinductive.
Figure 2. In vitro osteoinductivity of PLGA/HA composite scaffolds. (A) MSC proliferation as measured by the Quant-iT PicoGreen Assay. (B)
Mineralization as assessed using alizarin red staining of deposited calcium. Cell-based mineralization was quantified by subtracting scaffold-based
mineralization and normalizing by cell count. (C) MSC OCN production induced by seeding on PLGA/HA scaffolds. Cell-secreted OCN as determined
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Intrinsic osteoinductivity of composite scaffolds
The biological basis of CaP osteoinductivity has yet to be
completely characterized. In fact, some CaPs, like highly
crystalline HA, have been found to possess limited intrinsic
osteoinductivity [28]. The prevailing CaP osteoinduction theories
focus around three complementary but disparate ideas: 1) local
presence of calcium and phosphate ions, 2) mechanobiological
triggering due to surface topography, and 3) scaffold absorption
and presentation of endogenously released osteogenic growth
factors [29]. Recent research has shown that human periosteal
stem cells undergo osteogenic differentiation when exposed to
calcium and phosphate ions without any supplemental factors
providing strong evidence that the ions themselves possess intrinsic
osteoinductivity [30]. The results herein align with other research
that has shown CaP ion release correlated to the quality and
quantity of new in vivo bone formation [28]. In situ precipitated HA
present in the PLGA/HA scaffolds has been found to be of low
crystallinity [19]. When submerged in phosphate buffered saline
(PBS), both PLGA/HA scaffold compositions release approxi-
mately the same significant quantities of calcium ions whereas
PLGA scaffolds showed no ion release (Fig. 3A). We theorized that
calcium and phosphate ions released from PLGA/HA scaffolds
induce seeded MSCs to produce their own desirable biomolecules.
Interestingly, a recent study demonstrated that calcium ions
induce bone marrow derived stromal cells to undergo osteogenesis
through the ERK1/2 signaling pathway resulting in downstream
BMP-2 gene expression [31]. Utilizing a BMP-2 ELISA, it was
discovered that MSCs seeded on PLGA/HA scaffolds produced
and secreted significant quantities of BMP-2 that increased over
time (Fig. 3B). MSCs seeded on PLGA scaffolds were found to
secrete low levels of detectable BMP-2 which is most likely due to
the small quantities of calcium and phosphate ions, b-glycero-
phosphate, ascorbic acid, and Vitamin-D3 found in the media. To
our knowledge, CaP induction of cell-based bone morphogenetic
protein production has not been previously shown in the literature.
This data provides strong evidence that calcium and phosphate
ions act as simple signaling molecular triggers capable of inducing
a cell-based BMP-2 autocrine and paracrine osteoinduction loop.
Growth factor addition does not enhance scaffold
osteoinductivity
To further investigate materials-based osteoinductivity, rhBMP-
2 was surface-adsorbed to the scaffolds. By loading rhBMP-2 onto
both PLGA and PLGA/HA scaffolds, the comparative and
synergistic osteoinductive effects of HA and rhBMP-2 were
studied. Since ion release and osteoinductivity for both the
PLGA/HA scaffolds compositions were found to be highly similar,
only the more mechanically competent 83/17 PLGA/HA [19]
was utilized for this study. Different dosages (0.9 mg, 3.75 mg, or
15 mg) of rhBMP-2 were first surface-adsorbed onto either PLGA
or 83/17 PLGA/HA scaffolds by lyophilization. MSCs were then
seeded onto TCP, PLGA scaffolds, rhBMP-2 loaded PLGA
scaffolds, 83/17 PLGA/HA scaffolds, or rhBMP-2 loaded 83/17
PLGA/HA scaffolds and assessed for their cell proliferation,
protein production, and mineralization at 3, 7, 14, and 21 days.
MSCs seeded on either scaffold composition had higher cell counts
Figure 3. PLGA/HA composite scaffold ion release mediates cell-based BMP-2 production. (A) Scaffold-based ion release as determined
by the Calcium (CPC) Liquicolor assay. (B) BMP-2 secreted from cells as analyzed by ELISA and normalized by cell count. ND= Not Detectable; N= 4;
p,0.05 for * = TCP (same time point), += PLGA (same time point),#= Same Experimental Group (Day 3), $= Same Experimental Group (Day 7), and
&= Same Experimental Group (Day 14).
doi:10.1371/journal.pone.0101627.g003
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correlating to increased rhBMP-2 loading which became statisti-
cally significant over time (Fig. 4A) and is consistent with the role
of rhBMP-2 as a mitogen [32]. MSC osteogenesis was analyzed by
OCN secretion and scaffold mineralization. Overall cell-secreted
OCN production increased slightly according to a trend of
increasing rhBMP-2 quantity, but these differences disappeared
when protein production was normalized by cell count (Fig. 4B).
For cell-based mineralization, a similar trend was seen where the
slight effect of rhBMP-2 loading was negated by cell count
normalization (Fig. 4C). For both OCN secretion and cell-based
mineralization, MSC osteogenesis was directly related to the
presence of HA in the scaffolds and could not be induced or
enhanced by the incorporation of rhBMP-2.
The effect of scaffold loaded rhBMP-2 on MSCs to produce
their own BMP-2 was also investigated in this study. Total BMP-2
was quantified using a BMP-2 ELISA and cell-based BMP-2
production was determined by subtracting out the rhBMP-2
release from acellular scaffolds (Fig. 5A). The presence of large
supraphysiological quantities of rhBMP-2 on the scaffolds was
unable to induce MSCs to increase endogenous production of
BMP-2. Protein release from rhBMP-2 loaded acellular scaffolds
(PLGA 15 and 83/17 PLGA/HA 15) or secreted from rhBMP-2
free cellular scaffolds (PLGA Cells and 83/17 Cells) were analyzed
Figure 4. In vitro osteoinductivity of BMP-2 loaded PLGA/HA composite scaffolds. (A) MSC proliferation as measured by Quant-iT
PicoGreen Assay. (B) Mineralization as assessed by alizarin red staining of deposited calcium. Cell-based mineralization was quantified by subtracting
out scaffold-based mineralization and normalizing by cell count. (C) MSC OCN production induced by BMP-2 loaded PLGA/HA scaffolds. Cell-secreted
OCN determined by ELISA and normalized by cell count. ND= Not Detectable; N= 4; p,0.05 for += PLGA (same BMP-2 loading and same time
point), $= Same Experimental Group (Day 7), and &= Same Experimental Group (Day 14).
doi:10.1371/journal.pone.0101627.g004
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by BMP-2 ELISA (Fig 5B). Intact rhBMP-2 was released by both
scaffold compositions in a triphasic profile of burst (day 1), lag
(days 2–17), and secondary release (days 18–21) with PLGA 15
scaffolds releasing two-fold to three-fold greater amounts of
rhBMP-2 than 83/17 PLGA/HA 15 scaffolds. This difference in
rhBMP-2 release is attributed to the stronger protein binding that
occurs to the HA in composite scaffolds than PLGA [23]. Cell-
based BMP-2 was not secreted until 3-4 days post-incubation.
Figure 5. Cell-based BMP-2 production unaltered by loading exogenous BMP-2 on scaffolds. (A) Total BMP-2 as analyzed by ELISA and
normalized by cell count. (B) Cumulatively released BMP-2 from protein-loaded scaffolds (top) or MSCs seeded on protein-free scaffolds (bottom).
ND= Not Detectable; N= 4; p,0.05 for * = TCP (same time point), += PLGA (same BMP-2 loading and same time point), .= PLGA 15 (same time
point), ‘= 83/17 15 (same time point), #= Same Experimental Group (Day 3), $= Same Experimental Group (Day 7), and &= Same Experimental
Group (Day 14).
doi:10.1371/journal.pone.0101627.g005
Figure 6. Induceron theory. Inducerons (simple signaling molecules) are capable of inducing stem and progenitor cells to undergo desired
differentiation and to produce their own endogenous growth factors. While evidence has been provided in this paper for osteoinductive inducerons,
other research has shown that a variety of different inducerons are capable of carrying out other desirable inductive cellular functions.
doi:10.1371/journal.pone.0101627.g006
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MSCs seeded on PLGA scaffolds produced low quantities of BMP-
2 whereas MSCs seeded on 83/17 PLGA/HA scaffolds showed
geometrically increasing BMP-2 secretion over time. By day 10,
BMP-2 production from cells seeded on 83/17 PLGA/HA was
found to be significantly greater than cells seeded on PLGA. While
the burst release of rhBMP-2 may not be ideal for osteoinduction,
BMP-2 release during the lag phase and secondary phase was
found to be one to three orders of magnitude greater than the
largest quantity of cell-based BMP-2 secreted. Additionally, it
should be noted that greater than 90% of loaded rhBMP-2 was still
adsorbed to both scaffold compositions at Day 21. Since BMPs are
capable of carrying out their osteoinductive function without being
internalized [33], the rhBMP-2 loaded scaffolds exposed seeded
MSCs to at least four orders of magnitude greater quantities of
BMP-2 than cells seeded on protein-free 83/17 PLGA/HA
scaffolds secreted throughout the experiment. The addition of
supraphysiological rhBMP-2 dosages was unable to modulate cell-
based BMP-2 production; instead the presence of HA in the
PLGA/HA scaffolds was responsible for cell-based BMP-2
secretion.
Discussion
The results presented in this report corroborate our novel
theory that the simple signaling molecules of calcium and
phosphate ions possess intrinsic osteoinductivity which is carried
out by the induction of cell-based osteoinductive protein growth
factor (BMP-2) production and secretion. Review of published
biochemical research has revealed that there exist a number of
simple signaling molecules that possess similar behavior to calcium
and phosphate ions for which we have collectively termed
inducerons (Fig. 6). These small molecules are uniquely capable
of inducing stem and progenitor cell differentiation down desired
lineages utilizing protein growth factor-based inductive autocrine
and paracrine loops. The problems associated with using BMP-2
in bone graft substitutes such as cost and long-term safety are also
issues with utilizing protein growth factors in other translational
biomedical engineering strategies. Since these inductive molecules
can be released from stable, inexpensive materials (e.g. CaP), their
long-term delivery can be achieved through a wide variety of
controlled release strategies compared to the relatively few options
available for fragile, expensive protein growth factors. In the
United States, more than 115,000 people are currently on the
organ transplantation list and over 7,000 people will die each year
waiting for viable donor organs to become available [34].
Furthermore, the quality of life for those individuals that do
receive transplanted organs is severely hampered by high organ
rejection rates (23.7%–57.3% at 5 years post-transplantation) [34]
and the side effects associated with immunosuppressive drugs [35].
Utilizing the principles of biology, engineering, morphogenesis,
stem cell technology, and materials cues, regenerative engineering
represents a novel approach in which the body is induced to
regenerate its own complex tissues and organs. This new concept
of inducerons may compel regenerative engineering strategies to
become the new gold standard in complex tissue and organ
replacement therapies.
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